A Brazilian technology institute signed a deal on Wednesday to produce Russia's coronavirus vaccine, despite state health authorities expressing concerns over the effectiveness and safety of the drug.

Government-run Parana's Technology Institute, known as Tecpar signed the deal with the Russian Direct Investment Fund (RDIF).

Also read |&nbsp;<a href="https://www.wionews.com/world/argentina-mexico-to-produce-astrazeneca-covid-19-vaccine-320099">Argentina, Mexico to produce AstraZeneca COVID-19 vaccine</a>

"This is a very objective memorandum of understanding on technological exchange. It does not impose obligations, it simply enables us to work together," Jorge Callado, head of Tecpar said.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/amid-scepticism-russia-says-will-produce-5-million-vaccine-doses-by-december-january-320006">Amid scepticism, Russia says will produce 5 million vaccine doses by December-January</a>

RDIF said that the objective of the deal is to "organise the production of the Sputnik V vaccine and its distribution in Brazil and other Latin American countries."

Sputnik V is yet to receive regulatory approval from Brazil and officials from Parana have said that Phase 3 clinical trials of the vaccine are to be done before the production kicks off.&nbsp;

However, the institute has said that the vaccine could be imported earlier than the production date if it gets approval from Brazil's federal health regulator Anvisa.

Meanwhile, health experts and former officials on Tuesday expressed their concerns over the safety of the vaccine, which was not a part of massive human trials to convince many professionals of its safety.&nbsp;

On Tuesday, Russian President Vladimir Putin announced that Sputnik V has been given state approval as the drug to treat coronavirus, adding that his daughter has also received a shot of the vaccine and felt "well".&nbsp;

 
&nbsp;

A Brazilian technology institute signed a deal on Wednesday to produce Russia's coronavirus vaccine, despite state health authorities expressing concerns over the effectiveness and safety of the drug.

A Brazilian technology institute signed a deal on Wednesday to produce Russia's coronavirus vaccine, despite state health authorities expressing concerns over the effectiveness and safety of the drug. Government-run Parana's Technology Institute, known as Tecpar signed the deal with the Russian Direct Investment Fund (RDIF). Also read | Argentina, Mexico to produce AstraZeneca COVID-19 vaccine "This is a very objective memorandum of understanding on technological exchange. It does not impose obligations, it simply enables us to work together," Jorge Callado, head of Tecpar said. Also read | Amid scepticism, Russia says will produce 5 million vaccine doses by December-January RDIF said that the objective of the deal is to "organise the production of the Sputnik V vaccine and its distribution in Brazil and other Latin American countries." Sputnik V is yet to receive regulatory approval from Brazil and officials from Parana have said that Phase 3 clinical trials of the vaccine are to be done before the production kicks off. However, the institute has said that the vaccine could be imported earlier than the production date if it gets approval from Brazil's federal health regulator Anvisa. Meanwhile, health experts and former officials on Tuesday expressed their concerns over the safety of the vaccine, which was not a part of massive human trials to convince many professionals of its safety. On Tuesday, Russian President Vladimir Putin announced that Sputnik V has been given state approval as the drug to treat coronavirus, adding that his daughter has also received a shot of the vaccine and felt "well".

Brazilian state signs deal to produce Russia's coronavirus vaccine

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of a COVID-19 vaccine candidate, developed by the University of Oxford, in the country.

Government officials told PTI that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19.

As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, "Covishield", on healthy adults in India, the officials said.

"The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said.

"As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said.

Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa.

The officials said that the SII had submitted a revised proposal on Wednesday after the expert panel on Tuesday, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information.

The panel has also recommended that the clinical trial sites which have been proposed for the study be distributed across India.

According to the revised proposal, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore.

"According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of ''Covishield'' on healthy Indian adults," the official said.

The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for COVID-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine.

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of a COVID-19 vaccine candidate, developed by the University of Oxford, in the country.

The Drugs Controller General of India (DCGI) has given nod to the Serum Institute of India (SII) for conducting phase 2 and 3 human clinical trials of a COVID-19 vaccine candidate, developed by the University of Oxford, in the country. Government officials told PTI that the approval for conducting phase 2 and 3 clinical trials by the SII was granted by DCGI Dr V G Somani late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee on COVID-19. As a rapid regulatory response, the expert panel at the Central Drugs Standard Control Organisation (CDSCO) on Friday, after a detailed deliberation and considering the data generated on the vaccine candidate in phase 1 and 2 of the Oxford University trial, had recommended granting permission for phase 2 and 3 clinical trials of the potential vaccine, "Covishield", on healthy adults in India, the officials said. "The firm has to submit safety data, evaluated by the Data Safety Monitoring Board (DSMB), to the CDSCO before proceeding to phase 3 clinical trials," a senior official said. "As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals," the official said. Currently, phase 2 and 3 clinical trials of the Oxford vaccine candidate is going on in the United Kingdom, phase 3 clinical trial in Brazil and phase 1 and 2 clinical trials in South Africa. The officials said that the SII had submitted a revised proposal on Wednesday after the expert panel on Tuesday, following deliberation over its application, had asked it to revise its protocol for the phase 2 and 3 clinical trials besides seeking some additional information. The panel has also recommended that the clinical trial sites which have been proposed for the study be distributed across India. According to the revised proposal, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS Delhi, B J Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences (RMRIMS) in Patna, Post Graduate Institute of Medical Education and Research in Chandigarh, AIIMS-Jodhpur, Nehru Hospital in Gorakhpur, Andhra Medical College in Visakhapatnam and JSS Academy of Higher Education and Research in Mysore. "According to the application, it would conduct an observer-blind, randomised controlled study to determine the safety and immunogenicity of ''Covishield'' on healthy Indian adults," the official said. The SII, which has partnered with AstraZeneca, for manufacturing the Oxford vaccine candidate for COVID-19 had submitted its first application to the DCGI on July 25 seeking permission for conducting the phase 2 and 3 trials of the potential vaccine.

Oxford COVID vaccine: Serum institute gets nod for Phase 2, 3 human trials

As the global race for a COVID-19 vaccine heats up, how close are we to a vaccine? And which country will get it first? Watch: Vaccine Wars, Explained, a Wion Wideangle special

WION Wideangle | Vaccine wars explained | WION | COVID-19 Vaccine

The Trump administration’s $765 million loan to the Eastman Kodak Co. for its launch of a business making pharmaceutical ingredients sent shares of the iconic camera company soaring.

Kodak re-brands itself as drug maker amid COVID pandemic

In the latest non-human trial for US companies, the Moderna COVID-19 vaccine protected 16 monkeys against COVID-19. Watch report.

Human trials begins for Moderna vaccine: Successful on monkey

Keeping borders closed to halt the spread of COVID-19 is unsustainable, the World Health Organization said Monday, urging countries to adopt comprehensive strategies based on local knowledge of where the virus is spreading. 
 
<a href="https://www.wionews.com/world/europe-tightens-coronavirus-restrictions-amid-fresh-outbreaks-316363">ALSO READ | Europe tightens coronavirus restrictions amid fresh outbreaks</a> 
 
Border closures and travel restrictions remain an important part of many countries' strategy to combat the novel coronavirus.

At the same time, rising cases in a range of countries in Europe and elsewhere that had loosened measures after appearing to get their outbreaks under control have spurred discussions of possible fresh border closures.

<div class="videoWrapper trancodeVideo">&nbsp;</div>

But the UN health body warned that such measures can not be kept up indefinitely, and are also only useful when combined with a wide range of other measures to detect and break chains of transmission.

"Continuing to keep international borders sealed is not necessarily a sustainable strategy for the world's economy, for the world's poor, or for anybody else," Michael Ryan, WHO emergencies director, told journalists in a virtual briefing.

"It is going to be almost impossible for individual countries to keep their borders shut for the foreseeable future," he said, pointing out that "economies have to open up, people have to work, trade has to resume."

He acknowledged that when it comes to COVID-19, it is impossible to have a "global one size fits all policy" because outbreaks are developing differently in different countries.

While countries with rampant community transmission may need to use the blunt instrument of lockdowns to gain control of the situation, others should be burrowing down to get a clear overview of where and how the virus is spreading at a local level.

Don't 'release pressure'

They should be prepared to tighten or loosen measures accordingly, he said, warning against "releasing pressure" on the virus, which has killed some 650,000 people and infected 16.3 million worldwide.

"Release pressure on the virus and the numbers can creep back up."

Maria Van Kerkhove, the WHO's technical lead on COVID-19, said that instead of expecting drastic measures to keep the virus in check, people need to adapt their behaviours for the long haul.

"What we're going to have to figure out... is what our new normal looks like?" she told reporters.

"Our new normal includes physical distancing from others, (and) wearing masks where appropriate," she said.

"Our new normal includes us knowing where this virus is every day, where we live, where we work, where we want to travel."

Keeping borders closed to halt the spread of COVID-19 is unsustainable, the World Health Organization said Monday, urging countries to adopt comprehensive strategies based on local knowledge of where the virus is spreading.

Keeping borders closed to halt the spread of COVID-19 is unsustainable, the World Health Organization said Monday, urging countries to adopt comprehensive strategies based on local knowledge of where the virus is spreading. ALSO READ | Europe tightens coronavirus restrictions amid fresh outbreaks Border closures and travel restrictions remain an important part of many countries' strategy to combat the novel coronavirus. At the same time, rising cases in a range of countries in Europe and elsewhere that had loosened measures after appearing to get their outbreaks under control have spurred discussions of possible fresh border closures. But the UN health body warned that such measures can not be kept up indefinitely, and are also only useful when combined with a wide range of other measures to detect and break chains of transmission. "Continuing to keep international borders sealed is not necessarily a sustainable strategy for the world's economy, for the world's poor, or for anybody else," Michael Ryan, WHO emergencies director, told journalists in a virtual briefing. "It is going to be almost impossible for individual countries to keep their borders shut for the foreseeable future," he said, pointing out that "economies have to open up, people have to work, trade has to resume." He acknowledged that when it comes to COVID-19, it is impossible to have a "global one size fits all policy" because outbreaks are developing differently in different countries. While countries with rampant community transmission may need to use the blunt instrument of lockdowns to gain control of the situation, others should be burrowing down to get a clear overview of where and how the virus is spreading at a local level. Don't 'release pressure' They should be prepared to tighten or loosen measures accordingly, he said, warning against "releasing pressure" on the virus, which has killed some 650,000 people and infected 16.3 million worldwide. "Release pressure on the virus and the numbers can creep back up." Maria Van Kerkhove, the WHO's technical lead on COVID-19, said that instead of expecting drastic measures to keep the virus in check, people need to adapt their behaviours for the long haul. "What we're going to have to figure out... is what our new normal looks like?" she told reporters. "Our new normal includes physical distancing from others, (and) wearing masks where appropriate," she said. "Our new normal includes us knowing where this virus is every day, where we live, where we work, where we want to travel."

Keeping international borders sealed unsustainable Covid-19 strategy: WHO

Moderna's vaccine against COVID-19 could be rolled out by the end of this year, US&nbsp;officials said on Monday, after the drugmaker announced the start of a 30,000-subject trial to demonstrate it is safe and effective, the final hurdle prior to approval by global regulators. 
 
<a href="https://www.wionews.com/world/moderna-inc-to-begin-final-testing-stage-of-coronavirus-vaccine-on-30000-volunteers-in-july-305148">ALSO READ | Moderna Inc to begin final testing stage of coronavirus vaccine on 30,000 volunteers in July</a> 
 
The trial is the first such late-stage study under the Trump administration's program to speed development of measures against the novel coronavirus, adding to hope that an effective vaccine will help end the pandemic. Shares of Cambridge, Massachusetts-based Moderna rose 9%. 
 
<a href="https://www.wionews.com/world/israel-signs-agreement-with-moderna-for-potential-covid-19-vaccine-306725">ALSO READ | Israel signs agreement with Moderna for potential COVID-19 vaccine</a>

Moderna has received nearly $1 billion from the U.S. government, which is helping to bankroll several vaccine candidates under its Operation Warp Speed program.

More than 150 coronavirus vaccine candidates are in various stages of development, with some two dozen prospects having advanced to human testing.

"Having a safe and effective vaccine distributed by the end of 2020 is a stretch goal, but it's the right goal for the American people," National Institutes of Health (NIH) Director Francis Collins said in a release announcing the start of the large Phase III trial.

Manufacturers are ramping up production while testing is underway in order to respond as soon as possible to virus, which is still spreading rapidly around the world. COVID-19 has killed more about 650,000 people worldwide and battered economies.

Moderna could have tens of millions of doses ready when and if the vaccine is deemed safe and effective, Collins told reporters on a call.

The large late-stage trial is designed to evaluate the safety of Moderna's mRNA-1273 vaccine and determine if it can prevent symptomatic COVID-19 after two doses.

Anthony Fauci, the top U.S. infectious disease official, said a readout from the trial could come by November, December, or even earlier. Fauci said he was "not particularly concerned" about the vaccine's safety after seeing data from earlier, smaller trials.

The study also seeks to determine whether the vaccine can prevent coronavirus-related deaths.

Trial volunteers will receive two injections about 28 days apart of either 100 micrograms of mRNA-1273 or a placebo.

Results of a small early-stage study published earlier this month showed volunteers who got two doses of Moderna's vaccine had levels of virus-killing antibodies that exceeded the average seen in people who had recovered from COVID-19.

Moderna said it remains on track to deliver about 500 million doses a year, and possibly up to 1 billion doses a year, beginning 2021.

Moderna's vaccine against COVID-19 could be rolled out by the end of this year, US officials said on Monday, after the drugmaker announced the start of a 30,000-subject trial to demonstrate it is safe and effective, the final hurdle prior to approval by global regulators.

Moderna's vaccine against COVID-19 could be rolled out by the end of this year, US officials said on Monday, after the drugmaker announced the start of a 30,000-subject trial to demonstrate it is safe and effective, the final hurdle prior to approval by global regulators. ALSO READ | Moderna Inc to begin final testing stage of coronavirus vaccine on 30,000 volunteers in July The trial is the first such late-stage study under the Trump administration's program to speed development of measures against the novel coronavirus, adding to hope that an effective vaccine will help end the pandemic. Shares of Cambridge, Massachusetts-based Moderna rose 9%. ALSO READ | Israel signs agreement with Moderna for potential COVID-19 vaccine Moderna has received nearly $1 billion from the U.S. government, which is helping to bankroll several vaccine candidates under its Operation Warp Speed program. More than 150 coronavirus vaccine candidates are in various stages of development, with some two dozen prospects having advanced to human testing. "Having a safe and effective vaccine distributed by the end of 2020 is a stretch goal, but it's the right goal for the American people," National Institutes of Health (NIH) Director Francis Collins said in a release announcing the start of the large Phase III trial. Manufacturers are ramping up production while testing is underway in order to respond as soon as possible to virus, which is still spreading rapidly around the world. COVID-19 has killed more about 650,000 people worldwide and battered economies. Moderna could have tens of millions of doses ready when and if the vaccine is deemed safe and effective, Collins told reporters on a call. The large late-stage trial is designed to evaluate the safety of Moderna's mRNA-1273 vaccine and determine if it can prevent symptomatic COVID-19 after two doses. Anthony Fauci, the top U.S. infectious disease official, said a readout from the trial could come by November, December, or even earlier. Fauci said he was "not particularly concerned" about the vaccine's safety after seeing data from earlier, smaller trials. The study also seeks to determine whether the vaccine can prevent coronavirus-related deaths. Trial volunteers will receive two injections about 28 days apart of either 100 micrograms of mRNA-1273 or a placebo. Results of a small early-stage study published earlier this month showed volunteers who got two doses of Moderna's vaccine had levels of virus-killing antibodies that exceeded the average seen in people who had recovered from COVID-19. Moderna said it remains on track to deliver about 500 million doses a year, and possibly up to 1 billion doses a year, beginning 2021.

Moderna's COVID vaccine could be ready for use by year end: US 

Pharma companies are going after profits during the pandemic. Similarly, rich countries are looking after their self-interest. The UK has signed deals to secure 190 million vaccine doses, which is more than it requires

Gravitas: Who Is Making Profits During The Pandemic

Internationally, the race to find coronavirus vaccine is turning into a war.&nbsp;

India, on the other hand is secure in its self-knowledge. Whosoever comes up first in this vaccine race, India will be asked for its mass production.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/world/coronavirus-vaccine-wars-us-accuses-russian-hacker-group-apt29-of-trying-to-steal-data-314092">Coronavirus vaccine wars: US accuses Russian hacker group APT29 of trying to steal data</a>

One out of the three vaccines produced in the world is made in India. This has put India in a special position, but added great responsibility too.&nbsp;

Also read |&nbsp;<a href="https://www.wionews.com/india-news/indias-cadila-aims-to-complete-trial-of-coronavirus-vaccine-by-march-313985">India's Cadila aims to complete trial of coronavirus vaccine by March</a>

Around the world, there are over 140 vaccine candidates and only 11 so far have reached the stage of human trials.&nbsp;

<div class="videoWrapper trancodeVideo"><iframe allowfullscreen="" autoplay="1" class="includeVideo" frameborder="0" height="350" src="https://www.wionews.com/videos/gravitas-india-the-worlds-vaccine-producer-314138/embed" style="width:100%;max-width:560px;" width="560"></iframe></div>

From India, two candidates have made it to the human trials: Bharat Biotech's Covaxin and Zydus Cadila's ZyCoV-D.&nbsp;

India may or may not win this race, but no vaccine would succeed without India.&nbsp;

This is because discovering a vaccine is only half the battle won, the second, an equally important task is to manufacture them in great numbers.&nbsp;

To make vaccine accessible to all countries, mass production would be required with affordable prices.&nbsp;

And this responsibility rests on India's shoulders.&nbsp;

Every year, India produces three billion doses of vaccine and the cost of production and clinical trials are the lowest in the world.&nbsp;

For instance, the vaccine of rotavirus, a gastro-infection that particularly affects children is made 15 times cheaper by India.&nbsp;

The world's largest vaccine manufacturer, Serum Institute of India, makes more than 1.5 billion doses every year and the vaccines are exported to 170 countries.&nbsp;

The institute's role in eradication of polio must also be highlighted.&nbsp;

If Oxford University's COVID-19 vaccine gets a green signal, the company says, in one year, it can produce 700-800 billion doses.&nbsp;

And that too for 13 dollars, the cheapest in the world.&nbsp;

Bill Gates says only India is the country that can produce the vaccine for the entire world.&nbsp;

In April, even China admitted India's pharmaceutical prowess.&nbsp;

Currently, at least six Indian pharmaceutical companies are working with global institutes, which means no just one, but multiple COVID-19 vaccines could be made in India.&nbsp;

To sum it up, the Wuhan virus vaccine, developed anywhere in the world, it will be made in India.&nbsp;

 
&nbsp;

Internationally, the race to find coronavirus vaccine is turning into a war. India, on the other hand is secure in its self-knowledge. Whosoever comes up first in this vaccine race, India will be asked for its mass production.

Internationally, the race to find coronavirus vaccine is turning into a war. India, on the other hand is secure in its self-knowledge. Whosoever comes up first in this vaccine race, India will be asked for its mass production. Also read | Coronavirus vaccine wars: US accuses Russian hacker group APT29 of trying to steal data One out of the three vaccines produced in the world is made in India. This has put India in a special position, but added great responsibility too. Also read | India's Cadila aims to complete trial of coronavirus vaccine by March Around the world, there are over 140 vaccine candidates and only 11 so far have reached the stage of human trials. From India, two candidates have made it to the human trials: Bharat Biotech's Covaxin and Zydus Cadila's ZyCoV-D. India may or may not win this race, but no vaccine would succeed without India. This is because discovering a vaccine is only half the battle won, the second, an equally important task is to manufacture them in great numbers. To make vaccine accessible to all countries, mass production would be required with affordable prices. And this responsibility rests on India's shoulders. Every year, India produces three billion doses of vaccine and the cost of production and clinical trials are the lowest in the world. For instance, the vaccine of rotavirus, a gastro-infection that particularly affects children is made 15 times cheaper by India. The world's largest vaccine manufacturer, Serum Institute of India, makes more than 1.5 billion doses every year and the vaccines are exported to 170 countries. The institute's role in eradication of polio must also be highlighted. If Oxford University's COVID-19 vaccine gets a green signal, the company says, in one year, it can produce 700-800 billion doses. And that too for 13 dollars, the cheapest in the world. Bill Gates says only India is the country that can produce the vaccine for the entire world. In April, even China admitted India's pharmaceutical prowess. Currently, at least six Indian pharmaceutical companies are working with global institutes, which means no just one, but multiple COVID-19 vaccines could be made in India. To sum it up, the Wuhan virus vaccine, developed anywhere in the world, it will be made in India.

As global vaccine race intensifies, India has a crucial responsibility

UK, United States and Canada accused Russia on Thursday of trying to steal research-based information from experts and scientist seeking a COVID-19 vaccine. 
 
<a href="https://www.wionews.com/world/coronavirus-pandemic-engulfs-united-states-florida-new-epicentre-313851">Also read: Coronavirus pandemic engulfs United States; Florida new epicentre</a> 
 
Government-backed Russian hacking group was blamed for this ongoing cyber-espionage against organizations involved in the development of coronavirus vaccines and other health-care-related work, reflecting an escalation of security risks at a crucial time in the global response to the pandemic. 
 
<a href="https://www.wionews.com/world/us-sanctions-malaysias-surgical-glove-maker-over-forced-labour-amid-coronavirus-pandemic-313836">Also Read:&nbsp;US sanctions Malaysia's surgical glove maker over forced labour amid coronavirus pandemic</a>

All three countries have attributed the attack to a group named APT29, also known as Cozy Bear.

Britain’s National Cybersecurity Centre made the announcement, which was coordinated with authorities in the US and Canada.

The countries have said that this cyber-attack was almost certainly operating as part of Russian intelligence services.

"We condemn these despicable attacks against those doing vital work to combat the coronavirus pandemic," said Britain's National Cyber Security Centre (NCSC) Director of Operations Paul Chichester.

Cybersecurity researchers said an APT29 hacking tool was used against clients located in the United States, Japan, China and Africa over the last year.

Russian news agency RIA cited spokesman Dmitry Peskov as saying the Kremlin rejected London`s allegations, which he said were not backed by proper evidence.

It is completely unacceptable that the Russian Intelligence Services are targeting those working to combat the coronavirus pandemic,” Foreign Secretary Dominic Raab said in a statement.&nbsp;

“While others pursue their selfish interests with reckless behaviour, the U.K. and its allies are getting on with the hard work of finding a vaccine and protecting global health.”

In a separate announcement, Britain also accused "Russian actors" of trying to interfere in its 2019 election by trying to spread leaked documents online. Russia`s foreign ministry said those accusations were "foggy and contradictory".

Britain is expected to publish a long-delayed report into Russian influence in British politics next week.&nbsp;

Private-sector cybersecurity researchers who had spotted the WELLMESS malware over the last year were unaware of its Russian origins until Thursday.

In several cases, WELLMESS was found within U.S. pharmaceutical companies, said three investigators familiar with the matter, who spoke on condition of anonymity to discuss confidential information. The tool allowed hackers to stealthily gain remote access to secure computers. They declined to name the victims.

Britain and the United States said in May that networks of hackers were targeting national and international organisations responding to the pandemic. But such attacks have not previously been explicitly connected to the Russian state.&nbsp;

(With inputs from agencies)

UK, United States and Canada accused Russia on Thursday of trying to steal research-based information from experts and scientist seeking a COVID-19 vaccine. Also read: Coronavirus pandemic engulfs United States; Florida new epicentre Government-backed Russian hacking group was blamed for this ongoing cyber-espionage against organizations involved in the development of coronavirus vaccines and other health-care-related work, reflecting an escalation of security risks at a crucial time in the global response to the pandemic.

UK, United States and Canada accused Russia on Thursday of trying to steal research-based information from experts and scientist seeking a COVID-19 vaccine. Also read: Coronavirus pandemic engulfs United States; Florida new epicentre Government-backed Russian hacking group was blamed for this ongoing cyber-espionage against organizations involved in the development of coronavirus vaccines and other health-care-related work, reflecting an escalation of security risks at a crucial time in the global response to the pandemic. Also Read: US sanctions Malaysia's surgical glove maker over forced labour amid coronavirus pandemic All three countries have attributed the attack to a group named APT29, also known as Cozy Bear. Britain’s National Cybersecurity Centre made the announcement, which was coordinated with authorities in the US and Canada. The countries have said that this cyber-attack was almost certainly operating as part of Russian intelligence services. "We condemn these despicable attacks against those doing vital work to combat the coronavirus pandemic," said Britain's National Cyber Security Centre (NCSC) Director of Operations Paul Chichester. Cybersecurity researchers said an APT29 hacking tool was used against clients located in the United States, Japan, China and Africa over the last year. Russian news agency RIA cited spokesman Dmitry Peskov as saying the Kremlin rejected London`s allegations, which he said were not backed by proper evidence. It is completely unacceptable that the Russian Intelligence Services are targeting those working to combat the coronavirus pandemic,” Foreign Secretary Dominic Raab said in a statement. “While others pursue their selfish interests with reckless behaviour, the U.K. and its allies are getting on with the hard work of finding a vaccine and protecting global health.” In a separate announcement, Britain also accused "Russian actors" of trying to interfere in its 2019 election by trying to spread leaked documents online. Russia`s foreign ministry said those accusations were "foggy and contradictory". Britain is expected to publish a long-delayed report into Russian influence in British politics next week. Private-sector cybersecurity researchers who had spotted the WELLMESS malware over the last year were unaware of its Russian origins until Thursday. In several cases, WELLMESS was found within U.S. pharmaceutical companies, said three investigators familiar with the matter, who spoke on condition of anonymity to discuss confidential information. The tool allowed hackers to stealthily gain remote access to secure computers. They declined to name the victims. Britain and the United States said in May that networks of hackers were targeting national and international organisations responding to the pandemic. But such attacks have not previously been explicitly connected to the Russian state. (With inputs from agencies)

US, Britain, Canada accuse Russia of hacking Covid-19 vaccine research

The much-awaited COVID-19 vaccine developed by the University of Oxford has raised hopes after Phase one human trials showed some encouraging trends.&nbsp;

Blood samples taken from a group of volunteers who were involved in the study showed the vaccine stimulated antibodies and "killer T-cells", the Daily Telegraph reported.

Also read |&nbsp;<a href="https://www.wionews.com/world/8-world-leaders-demand-equal-global-access-to-coronavirus-vaccine-313620">8 world leaders demand equal global access to coronavirus vaccine</a>

Previous research has suggested T-cells can last in the body for years and help combat the viruses.

Also read |&nbsp;<a href="https://www.wionews.com/india-news/indian-pharma-industry-capable-of-producing-covid-19-vaccines-for-entire-world-bill-gates-313652">Indian pharma industry capable of producing COVID-19 vaccines for entire world: Bill Gates</a>

However, some experts also said only further trials could give a clear picture.&nbsp;

"Virtually any vaccine inevitably does this," Danny Altmann, a professor of immunology at the Imperial College London, said, reported Guardian, referring to the generation of antibodies and T-cells.&nbsp;

However, Dr Zania Stamataki, a senior lecturer in viral immunology at the University of Birmingham, said though the questions remains, the findings are a "very encouraging sign".&nbsp;

Some scientists have declined to comment and are waiting for the full publishing of results of the study on medical journal Lancet on Monday.&nbsp;

Also, experts said if the vaccine can generate immunity, the key would be to see for how long the immunity stands.

Recent studies have suggested that patients who have COVID-19 antibodies after getting recovered from the disease saw a signifcant fall in the number of antibodies over the three-month period.&nbsp;

US-based Moderna, producer of another leading COVID-19 vaccine candidate, said on Tuesday that it is all set to kick-off the final stage of human trials on July 27.&nbsp;

The much-awaited COVID-19 vaccine developed by the University of Oxford has raised hopes after Phase one human trials showed some encouraging trends. Blood samples taken from a group of volunteers who were involved in the study showed the vaccine stimulated antibodies and "killer T-cells", the Daily Telegraph reported.

The much-awaited COVID-19 vaccine developed by the University of Oxford has raised hopes after Phase one human trials showed some encouraging trends. Blood samples taken from a group of volunteers who were involved in the study showed the vaccine stimulated antibodies and "killer T-cells", the Daily Telegraph reported. Also read | 8 world leaders demand equal global access to coronavirus vaccine Previous research has suggested T-cells can last in the body for years and help combat the viruses. Also read | Indian pharma industry capable of producing COVID-19 vaccines for entire world: Bill Gates However, some experts also said only further trials could give a clear picture. "Virtually any vaccine inevitably does this," Danny Altmann, a professor of immunology at the Imperial College London, said, reported Guardian, referring to the generation of antibodies and T-cells. However, Dr Zania Stamataki, a senior lecturer in viral immunology at the University of Birmingham, said though the questions remains, the findings are a "very encouraging sign". Some scientists have declined to comment and are waiting for the full publishing of results of the study on medical journal Lancet on Monday. Also, experts said if the vaccine can generate immunity, the key would be to see for how long the immunity stands. Recent studies have suggested that patients who have COVID-19 antibodies after getting recovered from the disease saw a signifcant fall in the number of antibodies over the three-month period. US-based Moderna, producer of another leading COVID-19 vaccine candidate, said on Tuesday that it is all set to kick-off the final stage of human trials on July 27.

COVID-19 vaccine: Oxford university's phase one human trials shows encouraging trends

Russia's Sechenov university has completed the clinical trials of the world's first coronavirus vaccine on their volunteers. Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, told Sputnik that the first batch of volunteers will be discharged on Wednesday, whereas, the second will be discharged on July 20.&nbsp;

Also read:&nbsp;<a href="https://www.wionews.com/world/chinas-cansino-in-talks-for-covid-19-vaccine-phase-iii-trial-overseas-312714" hreflang="en">China's Cansino in talks for COVID-19 vaccine phase III trial overseas</a>

"Sechenov University has successfully completed tests on volunteers of the world's first vaccine against coronavirus," Tarasov said.

The university began the trials on June 18 and the vaccines were produced by Russia's Gamalei Institute of Epidemiology and Microbiology.

Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical and Vector-Borne Diseases at Sechenov University, said that the main objective of this stage of the study was to show the vaccine's safety for human health, which was successfully done.

"The safety of the vaccine is confirmed. It corresponds to the safety of those vaccines that are currently on the market," Lukashev told Sputnik.

According to Lukashev, further development plan for the vaccine is already determined by the developer's strategy, including the complexity of the epidemiological situation with the virus and the possibility of scaling up production.&nbsp;

"Sechenov University in a pandemic situation acted not only as an educational institution but also as a scientific and technological research center that is able to participate in the creation of such important and complex products as drugs ... We worked with this vaccine, starting with preclinical studies and protocol development, and clinical trials are currently underway," Tarasov noted.&nbsp;

Russia's Sechenov university has completed the clinical trials of the world's first coronavirus vaccine on their volunteers. Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, told Sputnik that the first batch of volunteers will be discharged on Wednesday, whereas, the second will be discharged on July 20.

Russia's Sechenov university has completed the clinical trials of the world's first coronavirus vaccine on their volunteers. Vadim Tarasov, the director of the Institute for Translational Medicine and Biotechnology, told Sputnik that the first batch of volunteers will be discharged on Wednesday, whereas, the second will be discharged on July 20. Also read: China's Cansino in talks for COVID-19 vaccine phase III trial overseas "Sechenov University has successfully completed tests on volunteers of the world's first vaccine against coronavirus," Tarasov said. The university began the trials on June 18 and the vaccines were produced by Russia's Gamalei Institute of Epidemiology and Microbiology. Alexander Lukashev, the director of the Institute of Medical Parasitology, Tropical and Vector-Borne Diseases at Sechenov University, said that the main objective of this stage of the study was to show the vaccine's safety for human health, which was successfully done. "The safety of the vaccine is confirmed. It corresponds to the safety of those vaccines that are currently on the market," Lukashev told Sputnik. According to Lukashev, further development plan for the vaccine is already determined by the developer's strategy, including the complexity of the epidemiological situation with the virus and the possibility of scaling up production. "Sechenov University in a pandemic situation acted not only as an educational institution but also as a scientific and technological research center that is able to participate in the creation of such important and complex products as drugs ... We worked with this vaccine, starting with preclinical studies and protocol development, and clinical trials are currently underway," Tarasov noted.

Russia's Sechenov University completes trials of world's first COVID-19 vaccine

An American biotechnology company has decided to begin their human trials of coronavirus vaccine in Australia. They announced on Tuesday and hoped that they could release a vaccine by the end of the year.&nbsp;

According to biotechnology company's research chief Dr Gregory Glenn, Novavax has commenced the first phase of the trial in which 131 volunteers will be tested. These volunteers will be from the cities of Melbourne and Brisbane and the test will look for early signs of the vaccine’s effectiveness.&nbsp;

“We are in parallel making doses, making vaccine in anticipation that we’ll be able to show it’s working and be able to start deploying it by the end of this year,” Glenn told a virtual press conference in Melbourne from Novavax’ headquarters in Maryland.

Many experimental vaccines are in early stages of testing or will begin testing across China, US, Europe. Vaccines are being created with different technologies, and work in different ways, which gives a possibility of at least one to succeed.&nbsp;

Most of the 'tested' vaccines aim to train the immunity system so that it recognizes the spike in the protein that studs the coronavirus' outer surface, instructing the body to react if it ever encountered the real infection. While other companies are making vaccines that are made using just the genetic code for that protein, and others use a harmless virus to deliver the protein-producing information. Still, other vaccine candidates are more old-fashioned, made with the killed whole virus.

Novavax has made another addition to the list of 'types of vaccines'. They have introduced the 'recombinant vaccine'. In these vaccines, Novavax has used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory. Scientists extracted and purified the protein, and packaged it into virus-sized nanoparticles.

An American biotechnology company has decided to begin their human trials of coronavirus vaccine in Australia. They announced on Tuesday and hoped that they could release a vaccine by the end of the year.

An American biotechnology company has decided to begin their human trials of coronavirus vaccine in Australia. They announced on Tuesday and hoped that they could release a vaccine by the end of the year. According to biotechnology company's research chief Dr Gregory Glenn, Novavax has commenced the first phase of the trial in which 131 volunteers will be tested. These volunteers will be from the cities of Melbourne and Brisbane and the test will look for early signs of the vaccine’s effectiveness. “We are in parallel making doses, making vaccine in anticipation that we’ll be able to show it’s working and be able to start deploying it by the end of this year,” Glenn told a virtual press conference in Melbourne from Novavax’ headquarters in Maryland. Many experimental vaccines are in early stages of testing or will begin testing across China, US, Europe. Vaccines are being created with different technologies, and work in different ways, which gives a possibility of at least one to succeed. Most of the 'tested' vaccines aim to train the immunity system so that it recognizes the spike in the protein that studs the coronavirus' outer surface, instructing the body to react if it ever encountered the real infection. While other companies are making vaccines that are made using just the genetic code for that protein, and others use a harmless virus to deliver the protein-producing information. Still, other vaccine candidates are more old-fashioned, made with the killed whole virus. Novavax has made another addition to the list of 'types of vaccines'. They have introduced the 'recombinant vaccine'. In these vaccines, Novavax has used genetic engineering to grow harmless copies of the coronavirus spike protein in giant vats of insect cells in a laboratory. Scientists extracted and purified the protein, and packaged it into virus-sized nanoparticles.

US company Novavax to conduct human trials of 'recombinant vaccine' in Australia

From a verbal threat to an official warning, the US has alleged China of launching cyber attacks to steal its Covid-19 vaccine research.

Is China stealing US vaccine research?

covid-vaccine

Covid Vaccine, News on Covid Vaccine, stories on Covid Vaccine, articles on Covid Vaccine, Covid Vaccine stories at Wion, Covid Vaccine news, Covid Vaccine latest news

covid vaccine